Germany has today voted to ban medical cannabis flower from its statutory health insurance scheme, in a controversial move critics say will have an outsized impact on the ‘seriously ill’.
The M&A scramble for Europe has continued at a fearsome pace over the last few weeks.
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling in.
This morning, the latest in a now-weekly series of stories in the British mainstream press was published in The Times, for the second week in a row taking aim at the advertising practices of some of the UK’s largest clinics.
The Irish government has appointed a public health academic to chair a formal review of its now five-year-old Medical Cannabis Access Programme (MCAP) following months of parliamentary pressure.
US Medicare patients have now been given access to cannabidiol (CBD) products through a landmark federal pilot scheme, helping boost cannabis stocks.
The White House’s commitment to push through rescheduling has been challenged by a Democratic Senator, who has demanded answers on the administration’s radio silence.
Cannabis remained Europe’s most commonly used drug in 2025, according to new wastewater analysis from the European Union Drugs Agency (EUDA), suggesting around 8.4% of European adults have consumed cannabis within the last year.
US cannabis rescheduling, much like President Donald Trump who is rightly credited for finally pushing it forward, has sucked all the oxygen out of the room for the last two years.
